By Fineline Cube 
Wuhan Healthgen Biotechnology Corp. (SHA: 688765) today announced that the Shanghai Stock Exchange has approved its application to sell RMB ordinary shares (A‑shares) on the Science and Technology Innovation Board (STAR Market). The company will issue 89,451,354 new shares at a final offering price of RMB 29.06 per share, raising approximately RMB 2.6 billion in capital.
Key Facts
| Item | Detail |
|---|---|
| Issuer | Wuhan Healthgen Biotechnology Corp. |
| Ticker | ORYZOGEN (688765) |
| Exchange | Shanghai Stock Exchange – STAR Market |
| Offering Size | 89,451,354 shares |
| Price per Share | RMB 29.06 |
| Capital Raised | ≈ RMB 2.6 billion |
| Share Type | New issue (no transfer of existing shares) |
Strategic Implications
- Capital Deployment – The proceeds will underpin Wuhan Healthgen’s R&D pipeline, accelerate clinical development of its biotech platform, and support strategic acquisitions.
- Market Positioning – Listing on the STAR Market, a high‑growth venue for science‑driven companies, enhances visibility among institutional investors and positions ORYZOGEN for future growth.
- Investor Outlook – The IPO’s strong pricing and sizeable capital raise signal robust demand for high‑tech biotech exposure in China’s evolving capital markets.
Forward‑Looking Statements
This release contains forward‑looking statements that involve risks and uncertainties. Actual results may differ materially.-Fineline Info & Tech